Checkpoint Therapeutics, Inc.
CKPTHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $41,000 | $103,000 | $192,000 | — | — | — |
| Operating income | −$56.2M | −$52.1M | −$58.3M | −$56.7M | −$23.2M | −$24.9M |
| Net income | −$56.2M | −$51.8M | −$62.6M | −$56.7M | −$23.1M | −$24.7M |
| Total assets | $7.5M | $5.4M | $13.3M | $55.7M | $42.6M | $27.0M |
| Total liabilities | $20.1M | $18.4M | $32.8M | $26.0M | $7.2M | $8.1M |
| Equity | −$12.6M | −$13.0M | −$19.5M | $29.7M | $35.4M | $18.8M |
| EPS (diluted) | $-1.42 | $-3.17 | $-7.09 | $-7.45 | — | — |
| Shares out. | 53.6M | 27.0M | 9.6M | 7.8M | 62.4M | 47.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −137009.8%
- Net margin
- −137170.7%
- Return on equity
- 445.5%
- Return on assets
- −752.8%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 269.0%
- Debt / equity
- —
- Book value / share
- $-0.24
- Revenue growth (YoY)
- −60.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -223.97distress
- Accruals / assets
- −336.5%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 5 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Beryl Capital Management LlcPassive (13G)Aug 14, 2025
- Fortress Biotech, Inc.Activist (13D)Jun 3, 2025
- Armistice Capital, LlcPassive (13G)May 15, 2025
- Glazer Capital, LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 30, 2025 | 697,503 | 1.0 | -76.4% |
| May 15, 2025 | 3.0M | 3.7 | -22.1% |
| Apr 30, 2025 | 3.8M | 3.6 | -18.6% |
| Apr 15, 2025 | 4.7M | 2.0 | -7.2% |
| Mar 31, 2025 | 5.0M | 3.1 | -1.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 30, 2025
- Shareholder voteMay 29, 2025
- Other material eventMay 22, 2025
- Results of operationsMay 13, 2025
- Entered a material agreementApr 15, 2025
- Results of operationsMar 28, 2025
- Entered a material agreement · Amended charter or bylaws · Other material eventMar 10, 2025
- Director / officer changeJan 10, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AAug 14, 2025
- 15-12GJun 9, 2025
- EFFECTJun 4, 2025
- EFFECTJun 4, 2025
- EFFECTJun 4, 2025
- EFFECTJun 4, 2025
- EFFECTJun 4, 2025
- EFFECTJun 4, 2025
- SCHEDULE 13D/AJun 3, 2025
- 4Jun 3, 2025
- 25-NSEMay 30, 2025
- 4OWNERSHIP DOCUMENTMay 30, 2025
- 4OWNERSHIP DOCUMENTMay 30, 2025
- 4OWNERSHIP DOCUMENTMay 30, 2025
- 4OWNERSHIP DOCUMENTMay 30, 2025
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.